PLATINUM-RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat ovarian cancer: experimental drug combo shows promise
Disease control CompletedThis study tested an experimental drug called ZN-c3, given alone or with another drug (niraparib), in 117 people with ovarian cancer that stopped responding to platinum-based chemotherapy. The goal was to find safe doses and see if the treatment could shrink tumors or slow the di…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated May 26, 2026 03:25 UTC
-
New drug cocktail shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedThis study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that had stopped responding to platinum chemotherapy and had already been treated with a PARP inhibitor. The goal was to see if the combo could slow or stop cancer growth. The…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for Hard-to-Treat ovarian cancer: experimental combo shows promise
Disease control CompletedThis early-phase trial tested an experimental drug called SL-172154 combined with either standard chemotherapy or a targeted therapy in 86 people with ovarian cancer that stopped responding to platinum-based treatments. The main goals were to check safety and find the best dose. …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New hope for tough ovarian cancer: drug combo shows promise in clinical trial
Disease control CompletedThis study tested whether adding a new drug called afuresertib to standard chemotherapy (paclitaxel) helps control ovarian cancer that has stopped responding to platinum-based treatments. About 150 women with this hard-to-treat cancer took part. The goal was to see if the combina…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated May 13, 2026 15:58 UTC